TP53 is the most frequently mutated gene in cancer, but these mutations remain
therapeutically non-actionable. Previous study reported arsenic trioxide could rescue
structural p53 mutations, endowing p53 mutations with thermostability and transcriptional
activity. Under Vivo and Vitro experiments, arsenic trioxide could reactivate mutated p53 to
inhibit tumor. This trial aimed to explore the efficacy and safety of arsenic trioxide in
refractory cancer patients with structural p53 mutations.